id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-1676-0005,FDA,FDA-2013-N-1676,Response from the United_States Government (USG) to the World Health Organization (WHO) re Questionnaire for Review of Dependence-producing Psychoactive Substances for the 36th Expert Committee on Drug Dependence,Other,Response(s),2014-09-02T04:00:00Z,2014,9,2014-09-02T04:00:00Z,,2014-09-02T21:57:46Z,,0,0,0900006481856980
FDA-2013-N-1676-0001,FDA,FDA-2013-N-1676,"International Drug Scheduling; Convention on Psychotropic
Substances; Single Convention on Narcotic Drugs; Tapentadol; Tramadol;
Ketamine; gamma-Butyrolactone; 22 Additional Substances; Request for
Comments",Notice,Request for Comments,2013-12-30T05:00:00Z,2013,12,2013-12-30T05:00:00Z,2014-01-30T04:59:59Z,2024-11-07T23:00:25Z,2013-31212,1,0,09000064814e192b